Crosstalk between epithelialmesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer

Endocrine-Related Cancer

Volumn 22, Issue 6, 2015, Pages 889-900

  Shiota, Masaki ^a   Itsumi, Momoe ^a   Takeuchi, Ario ^a   Imada, Kenjiro ^a   Yokomizo, Akira ^a   Kuruma, Hidetoshi ^b   Inokuchi, Junichi ^a   Tatsugami, Katsunori ^a   Uchiumi, Takeshi ^a   Oda, Yoshinao ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen receptor; Androgen deprivation therapy; Castration resistance; Epithelial mesenchymal transition; Prostate cancer; Twist1

Indexed keywords

ANDROGEN RECEPTOR; SB 525334; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; 6-(2-TERT-BUTYL-5-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-4-YL)QUINOXALINE; ANDROGEN; IMIDAZOLE DERIVATIVE; NUCLEAR PROTEIN; QUINOXALINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; TWIST1 PROTEIN, HUMAN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CELL INVASION; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL TRANSFORMATION; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MULTIMODALITY CANCER THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NUDE MOUSE; ORCHIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; RANDOMIZATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

ADENOCARCINOMA; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR PROTEINS; ORCHIECTOMY; PROSTATIC NEOPLASMS; QUINOXALINES; RANDOM ALLOCATION; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TWIST TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948159052     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0225     Document Type: Article

References (46)

1. Ansieau S, Morel AP, Hinkal G, Bastid J & Puisieux A 2010 TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 29 3173-3184. (doi:10.1038/onc.2010.92)
2. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS & Arteaga CL 2013 TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer. Journal of Clinical Investigation 123 1348-1358. (doi:10.1172/JCI65416)
3. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, De Wyngaert JK, Formenti SC et al. 2011 TGFb1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clinical Cancer Research 17 6754-6765. (doi:10.1158/1078-0432.CCR-11-0544)
4. Chen Y, Sawyers CL & Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology 8 440-448. (doi:10.1016/j.coph.2008.07.005)
5. Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB & Mo XB 2012 FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochemica 114 755-762. (doi:10.1016/j.acthis.2012.01.002)
6. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR & Akaza H 2009 Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. Journal of Clinical Oncology 27 4306-4313. (doi:10.1200/JCO.2008.21.5228)
7. Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE & Céraline J 2013 Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLo S ONE 8 e63466. (doi:10.1371/journal.pone.0063466)
8. Danila DC, Fleisher M & Scher HI 2011 Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research 17 3903-3912. (doi:10.1158/1078-0432.CCR-10-2650)
9. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
10. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RSII, Revelo MP, Bhowmick NA & Hayward SW 2011 Altered TGF-b signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Research 71 1272-1281. (doi:10.1158/0008-5472.CAN-10-3142)
11. Fuzio P, Ditonno P, Rutigliano M, Battaglia M, Bettocchi C, Loverre A, Grandaliano G & Perlino E 2012 Regulation of TGF-b1 expression by androgen deprivation therapy of prostate cancer. Cancer Letters 318 135-144. (doi:10.1016/j.canlet.2011.08.034)
12. Hara T, Miyazaki H, Lee A, Tran CP & Reiter RE 2008 Androgen receptor and invasion in prostate cancer. Cancer Research 68 1128-1135. (doi:10.1158/0008-5472.CAN-07-1929)
13. Imada K, Shiota M, Kohashi K, Kuroiwa K, Song Y, Sugimoto M, Naito S & Oda Y 2013 Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clinical Cancer Research 19 4638-4650. (doi:10.1158/1078-0432.CCR-12-3705)
14. Jacob K, Bosserhoff AK, Wach F, Knüchel R, Klein EC, Hein R & Buettner R 1995 Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. International Journal of Cancer. Journal International du Cancer 60 668-675. (doi:10.1002/ijc.2910600517)
15. Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ & Chang C 2002 Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. Journal of Biological Chemistry 277 43749-43756. (doi:10.1074/jbc.M205603200)
16. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C et al. 2005 Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Research 65 5153-5162. (doi:10.1158/0008-5472.CAN-04-3785)
17. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A & Gleave ME 2011 Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Research 71 5838-5849. (doi:10.1158/0008-5472.CAN-11-0994)
18. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI & Walker CL 2007 Tumor-specific efficacy of transforming growth factor-b RI inhibition in Eker rats. Clinical Cancer Research 13 3087-3099. (doi:10.1158/1078-0432.CCR-06-1811)
19. Li R, Wheeler T, Dai H, Frolov A, Thompson T & Ayala G 2004 High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology 28 928-934. (doi:10.1097/00000478-200407000-00013)
20. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH & Dehm SM 2011 Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research 71 2108-2117. (doi:10.1158/0008-5472.CAN-10-1998)
21. Liu YN, Liu Y, Lee HJ, Hsu YH & Chen JH 2008 Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Molecular and Cellular Biology 28 7096-7108. (doi:10.1128/ MCB.00449-08)
22. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E & Dong X 2014 Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33 3140-3150. (doi:10.1038/onc.2013.284)
23. Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E et al. 2014 The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumormicroenvironment and promotes prostate cancermetastasis. Cancer Discovery 4 1310-1325. (doi:10.1158/2159-8290.CD-13-1010)
24. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J et al. 2012 Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery 2 995-1003. (doi:10.1158/ 2159-8290.CD-12-0222)
25. Perry KT, Anthony CT, Case T & Steiner MS 1997 Transforming growth factor b as a clinical biomarker for prostate cancer. Urology 49 151-155. (doi:10.1016/S0090-4295(96)00426-8)
26. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R et al. 2008 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 26 1148-1159. (doi:10.1200/JCO.2007.12.4487)
27. Schmalhofer O, Brabletz S & Brabletz T 2009 E-cadherin b-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Reviews 28 151-166. (doi:10.1007/s10555-008-9179-y)
28. Shah PP & Kakar SS 2011 Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Letters 311 66-76. (doi:10.1016/j.canlet.2011.06.033)
29. Sharifi N, Gulley JL & Dahut WL 2010 An update on androgen deprivation therapy for prostate cancer. Endocrine-Related Cancer 17 R305-R315. (doi:10.1677/ERC-10-0187)
30. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito S 2010 Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29 237-250. (doi:10.1038/onc.2009.322)
31. Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y et al. 2011a Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocrine-Related Cancer 18 507-514. (doi:10.1530/ERC-11-0017)
32. Shiota M, Yokomizo A & Naito S 2011b Oxidative stress and androgen receptor signaling in the development and progression of castrationresistant prostate cancer. Free Radical Biology & Medicine 51 1320-1328. (doi:10.1016/j.freeradbiomed.2011.07.011)
33. Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A & Gleave ME 2012a Clusterinmediates TGF-b-induced epithelial-mesenchymal transition andmetastasis via Twist1 in prostate cancer cells. Cancer Research 72 5261-5272. (doi:10.1158/0008-5472.CAN-12-0254)
34. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, Tatsugami K, Uchiumi T, Oda Y & Naito S 2012b Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. Journal of Urology 187 707-714. (doi:10.1016/j.juro.2011.09.147)
35. Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K & Naito S 2012c Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. Journal of Urology 188 300-306. (doi:10.1016/j.juro.2012.02.2553)
36. Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T & Naito S 2013a Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor. Prostate 73 1336-1344. (doi:10.1002/pros.22681)
37. Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K et al. 2013bHsp27 regulates epithelialmesenchymal transition, metastasis, andcirculatingtumor cells in prostate cancer. Cancer Research 73 3109-3119. (doi:10.1158/0008-5472.CAN-12-3979)
38. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Song Y, Inokuchi J, Tatsugami K, Uchiumi T & Naito S 2014 Inhibition of protein Kinase C/Twist1 signaling augments anti-cancer effects of androgen deprivation and enzalutamide in prostate cancer. Clinical Cancer Research 20 951-961. (doi:10.1158/1078-0432.CCR-13-1809)
39. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ et al. 2012 Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Research 72 527-536. (doi:10. 1158/0008-5472.CAN-11-3004)
40. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL et al. 2010 Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine 16 1414-1420. (doi:10.1038/nm.2236)
41. Thiery JP & Sleeman JP 2006 Complex networks orchestrate epithelialmesenchymal transitions. Nature Reviews. Molecular Cell Biology 7 131-142. (doi:10.1038/nrm1835)
42. Wolff JM, Fandel T, Borchers H, Brehmer B Jr & Jakse G 1998 Transforming growth factor-b1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. British Journal of Urology 81 403-405. (doi:10.1046/j.1464-410x.1998.00560.x)
43. Ye L, Mason MD & Jiang WG 2011 Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Frontiers in Bioscience 16 865-897. (doi:10.2741/3725)
44. Zeisberg M & Neilson EG 2009 Biomarkers for epithelial-mesenchymal transitions. Journal of Clinical Investigation 119 1429-1437. (doi:10. 1172/JCI36183)
45. Zhu ML & Kyprianou N 2010 Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB Journal 24 769-777. (doi:10.1096/fj.09-136994)
46. Zhu ML, Partin JV, Bruckheimer EM, Strup SE & Kyprianou N 2008 TGF-b signaling and androgen receptor status determine apoptotic cross-talk in humanprostate cancer cells. Prostate 68287-295. (doi:10.1002/pros.20698)